2. Alzheimer’s is a disease in which the cells of nervous system in the brain are gradually degenerated and result in the decline in thinking and communicating abilities. The disease starts slowly and then gradually increases its severity with the passage of time. The disease affects the patient’s daily life in the sense that it decreases his/her thinking power and functionality. The people suffering from this disease are normally over 65 years in age. Aging is the most risky factor in the disease. People may suffer in early age from this disease but their percentage to overall diseased people is very low. The old age people are more likely to suffer from the disease. Alzheimer’s is the sixth leading cause of death in USA.

3.  People with age 65 years or older  Different ethnic groups  Both genders, Male and female  From different Social and Economic Classes

4.  ♦ Alzheimer's causing more than 70% of memory loss cases in people of age more than 71 years. ♦ All baby boomers will reach age of 65 in 2030 and people over 65 with Alzheimer’s will count to about 7.7 million with an increase of about 50% from 2009. ♦ The no. is expected to grow upto 11 to 16 million in 2050. There can be decrease in number only through medical breakthroughs or more effective treatment of disease. At that time, people of age more than 85 will contribute above 60% of the total affected people.

5.  Memory Loss  Difficulty in planning and solving problems  Difficulty in doing familiar tasks of routine life, at work or when free.  Uncertain with time or place  Decreased or poor thinking power  Minimizing the work or social responsibilities  Difficulty in recognizing visual images and spatial relationships  Difficulty in speaking or writing  Misplacing things and inability to recall the things and information  Sudden fluctuations in mood and personality

6. President Obama signs the National Alzheimer’s Project Act

7. Funding for Alzheimer's Disease Programs

8.  The activity-based Alzheimer care-treatment plan  Effectively evaluating assessment and care planning  Options and Program design methods to apply  Apply the different aspects of teamwork

9.  Immediately (4-8 weeks before) Set goals and needs Design a program Enlist healthcare professionals Secure location  2 to 4 weeks before Obtain materials and sponsors Marketing

10.  1 to 2 weeks before Review the goals and make necessary improvements Continue marketing and promotion Make sure that individuals will be available  Week of event Continue marketing See to last minute details

11.  Update plan  Suggestions  Assessments  Advisory committee

12. Plan must be organized to have access to all audiences in order to get proper promotion. Places where the target people can be found are: Community center Library Churches Schools Local health centers

13.  Internet Website  Local News  Local Radio  Newspaper

14. The reason and how it progresses regarding Alzheimer's disease is not known. Researches tells that it is due to plaques and tangles in the brain. The present treatment is not only possible according to disease symptoms but also available to prevent the progression of the disease. Till 2008 more than 500 ways have been tested to treat the disease. But unluckily, there is not any perfect way to cure the disease. Mental stimulation, exercise, and a balanced diet have been recommended only to delay. Alzheimer’s disease is not curable due to degeneration of brain. The caregivers should have social, psychological, physical, and economic elements to deal with the patient.

15.  Alzheimer’s Association (2011) Alzheimer News, retrieved from http://www.alz.orghttp://www.alz.org  Kimzey, J., (2010) Alzheimer’s Disease Threatens to Overwhelm U.S. Healthcare System, retrieved from, http://www.tenderrosehomecare.com/http://www.tenderrosehomecare.com/  Family and Consumer Science (2011). Health fair Planning Guide. Retrieved December 10, 2011, from http://www.fcs.tamu.eduhttp://www.fcs.tamu.edu  Birks J, Grimley Evans J (2009). Birks, Jacqueline. ed. "Ginkgo biloba for cognitive impairment and dementia". Cochrane Database Syst Rev (1): CD003120. doi:10.1002/14651858.CD003120.pub3. PMID 19160216. Retrieved 2011-12-11 from http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003120/frame.ht ml"Ginkgo biloba for cognitive impairment and dementia" doi10.1002/14651858.CD003120.pub3PMID19160216 http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003120/frame.ht ml  Eubanks LM, Rogers CJ, Beuscher AE et al. (November 2006). "A Molecular Link Between the Active Component of Marijuana and Alzheimer's Disease Pathology" (Free full text). Molecular Pharmaceutics 3 (6): 773–7. doi:10.1021/mp060066m. ISSN 1543-8384. PMC 2562334. PMID 17140265. Retrieved 2011-12-11 from http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2562 334."A Molecular Link Between the Active Component of Marijuana and Alzheimer's Disease Pathology"doi10.1021/mp060066m ISSN1543-8384PMC2562334PMID http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2562 334